Profil
Matthew T.
Seibt worked as the Chief Commercial Officer at Acer Therapeutics, Inc. from 2019 to 2023.
Prior to that, he held a former job at the same company from 2018.
He received his undergraduate degree from The University of Texas at Austin.
Anciens postes connus de Matthew T. Seibt
| Sociétés | Poste | Fin |
|---|---|---|
| ACER THERAPEUTICS INC. | Corporate Officer/Principal | 01/03/2023 |
Formation de Matthew T. Seibt
| The University of Texas at Austin | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Acer Therapeutics, Inc.
 Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Olpruva, Edsivo, and ACER-801. Olpruva is used for the treatment of urea cycle disorders. Edsivo is a type of celiprolol used in treating Vascular Ehlers-Danlos syndrome. ACER-001 treats menopausal related Vasomotor symptoms. The company was founded by Chris Schelling on March 15, 1991 and is headquartered in Newton, MA. | Health Technology |
